Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04645212 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT]

StatusActive, Not Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion dates: Jun 2025 to Jun 26, 2030v6 Show 4 more changesShow less
    • Primary endpoint revised
    • Eligibility criteria revised
    • Secondary endpoints: 6 to 12
    • Study description expanded, about 52 words
  2. Re-verified, no change to tracked fieldsv5
  3. Trial status: Enrolling by Invitation to Active, Not Recruiting
    • Enrollment target: estimated 30 to confirmed 23
    v4
  4. Re-verified, no change to tracked fieldsv3
  5. Site details revised at 2 of 9 sites
    • Eligibility criteria expanded, about 2 words
    v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
ADVM-022-07 is an observational long-term extension (OPTIC-EXT) study assessing safety and efficacy of ADVM-022 gene therapy product, in participants with neovascular, or exudative (wet), age-related macular degeneration (nAMD).
Trial Details
NCT Number NCT04645212
Lead Sponsor Adverum Biotechnologies, Inc.
Conditions
(from sponsor)		 Wet Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration
Related terms Blindness, Choroidal Neovascularization, Eye Diseases, Macular Degeneration, Retinal Degeneration, Retinal Diseases, Wet Macular Degeneration
Enrollment 23 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov